Business Update

PanGenomic Health Announces Completion of Consolidation

March 22, 2024

VANCOUVER, BC, March 21, 2024 /CNW/ – PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA) announces the completion of the consolidation (the “Consolidation”) of all of its issued and outstanding Class A Common Shares (“Common Shares”) on the basis of ten (10) pre-Consolidation Common Shares for every one (1) post-Consolidation Common Share was completed, effective March 21, 2024.

Immediately upon completion of the Consolidation, there were 10,496,748 Common Shares issued and outstanding. No fractional Common Shares were issued as a result of the Consolidation. Fractional Common Shares equal to or greater than one-half (1/2) were rounded up to the one whole number. Fractional Common Shares equal to less than one-half (1/2) were cancelled without any repayment of capital or other compensation.

The Common Shares began trading on a consolidated basis on the Canadian Securities Exchange (the “CSE”) on March 21, 2024.

The new CUSIP number for the post-Consolidation Common Shares is 69842E304 and the new ISIN is CA69842E3041. The Common Shares continue to trade on the CSE under the symbol “NARA”, and the Company’s name did not change.

Management of the Company believes that the Consolidation will provide the Company with a share structure that will better attract future capital financing and enhance growth opportunities.

About PanGenomic Health

PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company’s initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic Health’s mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

Jerry Lai
Investor Relations
PanGenomic Health Inc.
778 743 4642

Maryam Marissen
President & CEO
PanGenomic Health Inc.
778 743 4642

This news release includes certain statements that may be deemed “forward-looking statements”, including statements respecting the services to be provided by PanGenomic Health and the consideration to be paid to PanGenomic Health. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although PanGenomic Health believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PanGenomic Health can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including those risk factors discussed in PanGenomic Health’s Management’s Discussion and Analysis (“MD&A”) for the year ended December 31, 2022, which can be found under PanGenomic Health’s profile on  Except as required under applicable securities legislation, PanGenomic Health undertakes no obligation to publicly update or revise forward-looking information.

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.